Journal articles on the topic 'Docetaxel resistance'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Docetaxel resistance.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Kroon, Jan, Martin Puhr, Jeroen T. Buijs, Geertje van der Horst, Daniëlle M. Hemmer, Koen A. Marijt, Ming S. Hwang, et al. "Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer." Endocrine-Related Cancer 23, no. 1 (October 19, 2015): 35–45. http://dx.doi.org/10.1530/erc-15-0343.
Full textILHAN, Suleyman. "Effect of interleukin-8 on docetaxel resistance in prostate cancer cells: insights into the role of multidrug resistance 1 protein modulation." Cancer Insight 2, no. 1 (June 14, 2023): 53–67. http://dx.doi.org/10.58567/ci02010004.
Full textShen, Weiwei, Hailin Pang, Jiayu Liu, Jing Zhou, Feng Zhang, Lele Liu, Ningqiang Ma, Ning Zhang, Helong Zhang, and Lili Liu. "EpithelialMesenchymal Transition Contributes to Docetaxel Resistance in Human Non-Small Cell Lung Cancer." Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 22, no. 1 (October 23, 2014): 47–55. http://dx.doi.org/10.3727/096504014x14098532393473.
Full textFrancini, Edoardo, Fang-Shu Ou, Justin Rhoades, Eric G. Wolfe, Edward P. O’Connor, Gavin Ha, Gregory Gydush, et al. "Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer." Cancers 13, no. 16 (August 12, 2021): 4055. http://dx.doi.org/10.3390/cancers13164055.
Full textZu, Shulu, Weiming Ma, Pan Xiao, Yazhou Cui, Tianjia Ma, Chunwen Zhou, and Huaiqiang Zhang. "Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells." Urologia Internationalis 95, no. 1 (2015): 114–19. http://dx.doi.org/10.1159/000351263.
Full textLima, Thiago S., Diego Iglesias-Gato, Luciano D. O. Souza, Jan Stenvang, Diego S. Lima, Martin A. Røder, Klaus Brasso, and José M. A. Moreira. "Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance." Cancers 13, no. 6 (March 14, 2021): 1290. http://dx.doi.org/10.3390/cancers13061290.
Full textBukhari, Nedal, Kylea R. Potvin, D. Scott Ernst, Lori Sax, and Eric Winquist. "Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer." Journal of Clinical Oncology 35, no. 6_suppl (February 20, 2017): 260. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.260.
Full textGruber, Martina, Lavinia Ferrone, Martin Puhr, Frédéric R. Santer, Tobias Furlan, Iris E. Eder, Natalie Sampson, Georg Schäfer, Florian Handle, and Zoran Culig. "p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer." Endocrine-Related Cancer 27, no. 3 (March 2020): 187–98. http://dx.doi.org/10.1530/erc-19-0488.
Full textZhao, Song, Ilsa Coleman, Roger Coleman, and Peter Nelson. "Association of PARP inhibitors and docetaxel resistance through suppressing a tumor microenvironment-associated secretory program." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e22212-e22212. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22212.
Full textWróbel, Tomasz, Marcin Luty, Jessica Catapano, Elżbieta Karnas, Małgorzata Szczygieł, Katarzyna Piwowarczyk, Damian Ryszawy, et al. "CD44+ cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations." Stem Cells 38, no. 12 (October 2, 2020): 1544–56. http://dx.doi.org/10.1002/stem.3281.
Full textLiu, Rong-Zong, Mansi Garg, Xiao-Hong Yang, and Roseline Godbout. "Docetaxel-Induced Cell Death Is Regulated by a Fatty Acid-Binding Protein 12-Slug-Survivin Pathway in Prostate Cancer Cells." International Journal of Molecular Sciences 25, no. 17 (September 6, 2024): 9669. http://dx.doi.org/10.3390/ijms25179669.
Full textShimizu, Yasuomi, Satoshi Tamada, Minoru Kato, Yukiyoshi Hirayama, Yuji Takeyama, Taro Iguchi, Marianne Sadar, and Tatsuya Nakatani. "Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy." Journal of Clinical Medicine 7, no. 11 (November 16, 2018): 444. http://dx.doi.org/10.3390/jcm7110444.
Full textLiu, Xiao Dong, Yi Ju Hou, Lin Zhang, and Hui Ling Cao. "Compound Injection of Shenqi as a Reversal Drug on Docetaxel Resistant Human Lung Adenocarcinoma Cell A549/DTX." Advanced Materials Research 926-930 (May 2014): 1054–57. http://dx.doi.org/10.4028/www.scientific.net/amr.926-930.1054.
Full textSong, Liankun, Vyvyan Nguyen, Jun Xie, Matthew Tippin, Le TP Truong, Christopher A. Blair, Beverly Wang, Edward Uchio, and Xiaolin Zi. "Abstract 1687: ATPase copper transporting beta (ATP7B) contributes to acquired docetaxel resistance in human prostate cancer." Cancer Research 83, no. 7_Supplement (April 4, 2023): 1687. http://dx.doi.org/10.1158/1538-7445.am2023-1687.
Full textYin, Beibei, Ping Lu, Jing Liang, Wei Zhang, Meng Xin, Ke Pei, and Yan Li. "The ABCB1 3435C > T polymorphism influences docetaxel transportation in ovarian cancer." Journal of International Medical Research 47, no. 10 (September 6, 2019): 5256–69. http://dx.doi.org/10.1177/0300060519870354.
Full textRiedel, R. F., A. Porrello, E. Chenette, A. Potti, J. R. Nevins, and P. G. Febbo. "A genomic approach to identify mechanisms associated with chemotherapy resistance." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 2534. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.2534.
Full textAndo, Masashi, Toru Watanabe, Kazuhiro Nagata, Masaru Narabayashi, Isamu Adachi, and Noriyuki Katsumata. "Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance." Journal of Clinical Oncology 19, no. 2 (January 15, 2001): 336–42. http://dx.doi.org/10.1200/jco.2001.19.2.336.
Full textŞumnulu, Deniz, and Zeynep Doğanlar. "Aba enhances the apoptotic effect of docetaxel in the multidrug-resistant DU145 prostate cancer cell line." Archives of Biological Sciences, no. 00 (2024): 31. http://dx.doi.org/10.2298/abs240812031s.
Full textShimizu, Yasuomi, Minoru Kato, Yuji Takeyama, Kosuke Hamada, Taro Iguchi, Satoshi Tamada, and Tatsuya Nakatani. "The effect of androgen receptor splice variant 7 on the growth of castration-resistant prostate cancer and the efficacy of taxane chemotherapy." Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): 302. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.302.
Full textSchaaf, Zachary A., Shu Ning, Amy R. Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P. Lombard, Chengfei Liu, and Allen C. Gao. "Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer." Cancers 15, no. 21 (November 3, 2023): 5273. http://dx.doi.org/10.3390/cancers15215273.
Full textByun, Woong Sub, Eun Seo Bae, Jinsheng Cui, Hyen Joo Park, Dong-Chan Oh, and Sang Kook Lee. "Antitumor Activity of Pulvomycin via Targeting Activated-STAT3 Signaling in Docetaxel-Resistant Triple-Negative Breast Cancer Cells." Biomedicines 9, no. 4 (April 17, 2021): 436. http://dx.doi.org/10.3390/biomedicines9040436.
Full textSanchez, Bertha E., Nilesh Gupta, Meredith Mahan, Evelyn R. Barrack, Prem-veer Reddy, and Clara Hwang. "βIII-tubulin expression as a predictor of docetaxel resistance in metastatic castrate-resistant prostate cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e15174-e15174. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15174.
Full text&NA;. "Aberdeen researchers develop probe for docetaxel resistance." Oncology Times UK 4, no. 11 (November 2007): 7. http://dx.doi.org/10.1097/01434893-200711000-00007.
Full textFenner, Annette. "Antiandrogens reverse docetaxel resistance via ABCB1 inhibition." Nature Reviews Urology 12, no. 7 (June 9, 2015): 361. http://dx.doi.org/10.1038/nrurol.2015.135.
Full textLohiya, Vipin, Jeanny B. Aragon-Ching, and Guru Sonpavde. "Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer." Clinical Medicine Insights: Oncology 10s1 (January 2016): CMO.S34535. http://dx.doi.org/10.4137/cmo.s34535.
Full textMu, Chao-Feng, Fude Cui, Yong-Mei Yin, Hyun-Jong Cho, and Dae-Duk Kim. "Docetaxel-Loaded Chitosan-Cholesterol Conjugate-Based Self-Assembled Nanoparticles for Overcoming Multidrug Resistance in Cancer Cells." Pharmaceutics 12, no. 9 (August 19, 2020): 783. http://dx.doi.org/10.3390/pharmaceutics12090783.
Full textQian, Jiang, Sheliang Shen, Wei Chen, and Nianping Chen. "Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial–Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1α." BioMed Research International 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/4174232.
Full textAndo, Takayuki, Ayumu Hosokawa, Kohei Ogawa, Shinya Kajiura, Yuko Itaya, Akira Ueda, Yuji Tsukioka, Takashi Kobayashi, Naoki Horikawa, and Toshiro Sugiyama. "Efficacy of weekly paclitaxel in patients with advanced gastric cancer with prior docetaxel-containing chemotherapy." Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 127. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.127.
Full textBowers, Laura, Aneesha Kulkarni, and Stephen Hursting. "Obesity-Associated Leptin Signaling Promotes Chemotherapy Resistance in Basal-Like Breast Cancer: The Role of Tumor-Associated Macrophages." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 311. http://dx.doi.org/10.1093/cdn/nzaa044_010.
Full textMiyazawa, Yoshiyuki, Nobuaki Shimizu, Yutaka Takezawa, Toshiyuki Nakamura, Takeshi Miyao, Hiroshi Nakayama, Sota Kurihara, et al. "Exploratory study of prognostic factors in mCRPC patients who administered enzalutamide focusing on early PSA decline and PSA kinetics at PSA progression: Results of retrospective multicenter study." Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): 292. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.292.
Full textKomura, Kazumasa, Seong Ho Jeong, Kunihiko Hinohara, Fangfang Qu, Xiaodong Wang, Masayuki Hiraki, Haruhito Azuma, Gwo-Shu Mary Lee, Philip W. Kantoff, and Christopher J. Sweeney. "Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression." Proceedings of the National Academy of Sciences 113, no. 22 (May 16, 2016): 6259–64. http://dx.doi.org/10.1073/pnas.1600420113.
Full textHalder, Sushanta, Sakthivel Muniyan, Ramakanth Chirravuri-Venkata, Rama Krishna Nimmakayala, Palanisamy Nallasamy, Hareesh B. Nair, Moorthy P. Ponnusamy, Surinder K. Batra, and Parthasarathy Seshacharyulu. "Abstract 1756: Targeting LIFR/c-Myc Axis to Overcome Docetaxel Resistance in Prostate Cancer." Cancer Research 83, no. 7_Supplement (April 4, 2023): 1756. http://dx.doi.org/10.1158/1538-7445.am2023-1756.
Full textGlynn, Sharon A., Aidan Toner, Joe Lewis, Frank Sullivan, Laura Breen, Martin Clynes, and Francis J. Giles. "Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e15126-e15126. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15126.
Full textDing, Adeline B., Erika Heninger, Shannon R. Reese, Cristina Sanchez-de-Diego, Ravi C. Yada, Nan Sethakorn, Sheena C. Kerr, et al. "Abstract 635: Osteoclasts mediate chemotherapy resistance in a fully humanized microphysiologic system of prostate cancer bone metastases." Cancer Research 84, no. 6_Supplement (March 22, 2024): 635. http://dx.doi.org/10.1158/1538-7445.am2024-635.
Full textThangaretnam, Krishnapriya, Islam MD Obaidul, Heng Lu, Dunfa Peng, Nadeem Sidiq Bhat, Mohammed Soutto, and Zheng Chen. "Abstract 375: Smoking induces Wee1 expression through miRNA deregulation, promoting docetaxel resistance in esophageal adenocarcinoma." Cancer Research 83, no. 7_Supplement (April 4, 2023): 375. http://dx.doi.org/10.1158/1538-7445.am2023-375.
Full textDeshmukh, Chetan Dilip, Ganesh Divekar, Minish Mahendra Jain, Shailesh Arjun Bondarde, and Niraj Bhatt. "Pharmacologic differences in taxanes leading to difference in clinical activity and toxicity." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e13567-e13567. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13567.
Full textLi, Jia, Jing Ke, Cheng-lin Qin, and Xun Zhu. "LINC00680 modulates docetaxel resistance in breast cancer via the miR-320b/CDKL5 axis." International Journal of Immunopathology and Pharmacology 36 (January 2022): 039463202211056. http://dx.doi.org/10.1177/03946320221105608.
Full textThomson, Alastair, Adam Pollard, and Frances May Mark. "Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC)." Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): 298. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.298.
Full textMukherji, Deborah, Carmel Jo Pezaro, Diletta Bianchini, Andrea Zivi, and Johann Sebastian De Bono. "Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 17. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.17.
Full textNing, Yang-min, William D. Figg, and William L. Dahut. "Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide." Clinical Genitourinary Cancer 7, no. 2 (August 2009): E37—E38. http://dx.doi.org/10.3816/cgc.2009.n.020.
Full textHonma, Kimi, Kyoko Iwao-Koizumi, Fumitaka Takeshita, Yusuke Yamamoto, Teruhiko Yoshida, Kazuto Nishio, Shunji Nagahara, Kikuya Kato, and Takahiro Ochiya. "RPN2 gene confers docetaxel resistance in breast cancer." Nature Medicine 14, no. 9 (August 17, 2008): 939–48. http://dx.doi.org/10.1038/nm.1858.
Full textGanju, Aditya, Murali M. Yallapu, Sheema Khan, Stephen W. Behrman, Subhash C. Chauhan, and Meena Jaggi. "Nanoways to overcome docetaxel resistance in prostate cancer." Drug Resistance Updates 17, no. 1-2 (April 2014): 13–23. http://dx.doi.org/10.1016/j.drup.2014.04.001.
Full textScherbakov, Alexander M., Anna A. Basharina, Danila V. Sorokin, Ekaterina I. Mikhaevich, Iman E. Mizaeva, Alexandra L. Mikhaylova, Tatiana A. Bogush, and Mikhail A. Krasil’nikov. "Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance." Cancer Drug Resistance 6, no. 1 (2023): 103–15. http://dx.doi.org/10.20517/cdr.2022.96.
Full textvan Soest, Robert J., Martin E. van Royen, Ellen S. de Morrée, Erik A. C. Wiemer, Ron H. J. Mathijssen, Ronald De Wit, and Wytske M. van Weerden. "Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: Potential mechanism for cross-resistance in castration-resistant prostate cancer (CRPC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 5064. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5064.
Full textHaldar, Subhash, Rajeev Mishra, Sandrine Billet, Manish Thiruvalluvan, Veronica R. Placencio-Hickok, Anisha Madhav, Frank Duong, et al. "Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance." Proceedings of the National Academy of Sciences 117, no. 15 (April 1, 2020): 8515–23. http://dx.doi.org/10.1073/pnas.1910952117.
Full textPudova, Elena, Anastasiya Kobelyatskaya, Irina Katunina, Anastasiya Snezhkina, Kirill Nyushko, Maria Fedorova, Vladislav Pavlov, et al. "Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939." International Journal of Molecular Sciences 23, no. 21 (October 25, 2022): 12837. http://dx.doi.org/10.3390/ijms232112837.
Full textPouptsis, Athanasios, Styliani Germanou, Nick Waldron, Thomas Young, Madeha Khan, Simon Hughes, Debra Hannah Josephs, Sarah Maria Rudman, Deborah Enting, and Simon Chowdhury. "Primary resistance in docetaxel and androgen deprivation therapy in metastatic castrate sensitive prostate cancer patients." Journal of Clinical Oncology 36, no. 6_suppl (February 20, 2018): 342. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.342.
Full textRushworth, Linda K., Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, Holly Hall, Martin Bushell, Hing Y. Leung, and Rachana Patel. "In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer." Life Science Alliance 3, no. 12 (October 8, 2020): e202000770. http://dx.doi.org/10.26508/lsa.202000770.
Full textNoaman, Ali Sedeeq, and Ercan Caca. "Role of Gene Expression Profiling in Colorectal Cancer by Using Docetaxel and Lapatinib." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 15, no. 03 (September 25, 2024): 1607–12. http://dx.doi.org/10.25258/ijpqa.15.3.77.
Full textAssoun, Sandra, Luca Campedel, Morgan Roupret, Christophe Vaessen, Jerome Parra, Haide Angele Boostandoost, Eva Comperat, et al. "Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethystilbestrol in castration-resistant prostate cancer." Journal of Clinical Oncology 35, no. 6_suppl (February 20, 2017): e581-e581. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.e581.
Full text